An Open-label Extension Study to Assess the Long-term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia

Bristol-Myers Squibb0 个研究点目标入组 280 人开始时间: 待定最近更新: 2025年6月18日

适应症

试验速览

阶段: 不适用
状态: 进行中（未招募）
发起方
入组人数: 280
主要终点: -

研究概览研究设计入排标准结局指标研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional
分配方式: Randomized Controlled Trial
干预模型: Parallel Assignment
主要目的: Treatment Purpose
盲法: Open(masking Not Used)

入排标准

年龄范围: 18age old over 至 65age old under（—）
性别: All

入选标准

•Subject is aged >=18 to <=65 years at the time of randomization of Study KAR-012
•Subject has successfully completed the treatment period of Study KAR-012
•Subject has been compliant with the procedures in Study KAR-012 (in the Investigator's judgement)
•Subject has been compliant with their background antipsychotic drug in Study KAR-012 in the opinion of the Investigator and based on subject and informant reporting
•Note: Subjects are required to remain on the same appropriate approved APD as in Study KAR-012 and should stay on that same dose throughout the study.
•Subject is capable of providing signed Informed Consent Form before any study assessments will be performed
•Subject resides in a stable living situation, in the opinion of the Investigator
•Subject has identified a reliable informant/caregiver willing and able to assist with study activities as needed throughout the subject's participation in the study. The informant can complete the study visits assessments via phone (as per local regulations). In Bulgaria, the informant needs to be physically present at all study visits where the Investigator determines that his/her input would be beneficial.
•Women of childbearing potential (WOCP), or men whose sexual partners are WOCP, must be able and willing to use at least 1 highly effective method of contraception during the study and for at least 1 menstrual cycle (e.g., 30 days) after the last dose of study drug. Sperm donation is not allowed for 30 days after the final dose of the study drug. A female subject is considered to be a WOCP after menarche and until she is in a postmenopausal state for 12 months or otherwise permanently sterile (for which acceptable methods include hysterectomy, bilateral salpingectomy, or bilateral oophorectomy).

排除标准

•Risk for suicidal behavior during the study as determined by the Investigator's clinical assessment and/or Columbia-Suicide Severity Rating Scale (C-SSRS) as confirmed by the following:
•a. Subject answers ""Yes"" to ""suicidal ideation"" Item 4 (active suicidal ideation with some intent to act, without a specific plan) or Item 5 (active suicidal ideation with a specific plan and intent) on the C-SSRS
•b. Non-suicidal self-injurious behavior is not exclusionary
•Any clinically significant abnormalities, including any finding(s) from ECG, or laboratory test at Visit 6, and the physical examination, vital signs, at the EOT visit of Study KAR-012 that the Investigator, in consultation with the Medical Monitor are considered to jeopardize the safety of the subject
•Female subject is pregnant
•If, in the opinion of the Investigator (and/or Sponsor/ Medical Monitor), subject is unsuitable for enrollment in the study or subject has any finding that, in the view of the Investigator (and/or Sponsor /Medical Monitor), may compromise the safety of the subject or affect their ability to adhere to the protocol visit schedule or study requirements
•Risk of violent or destructive behavior as per Investigator's judgement
•Subjects participating in another investigational drug or device trial or planning on participating in another clinical trial during the study
•History or high risk of urinary retention, gastric retention, or narrow angle glaucoma as evaluated by the Investigator
•Subject is taking, or plans to take while in the study, any prohibited concomitant medication
•For all male subjects only, any one of the following:
•a. History of bladder stones
•b. History of recurrent urinary tract infections
•c. Serum prostate specific antigen (PSA) >10 ng/mL
•d. An International Prostate Symptom Score (IPSS) of 5 (almost always) on either item 1, 3, 5, or 6
•e. A sum of scores on IPSS items 1, 3, 5, and 6 of >=9 Note: IPSS will be required only for male subjects >= 45 years of age. Subjects already enrolled in the study who do not have available PSA values from Study KAR-012 for baseline value use in Study CN012-0009, will have these assessments at their next clinic visit planned after re-consenting to determine current eligibility.

结局指标

主要结局

Incidence of treatment-emergent adverse events (TEAEs)

次要结局

未报告次要终点

研究者

发起方

Bristol-Myers Squibb

相似试验

进行中（未招募）

1 期

ong-Term Evaluation of BIIB067

EUCTR2016-003225-41-PLBiogen Idec Research Limited183

已完成

不适用

An Extension Study to Assess the Long-Term Safety, Tolerability, Pharmacokinetics, and Effect on Disease Progression of BIIB078 Administered to Previously Treated Adults with C9ORF72-Associated Amyotrophic Lateral SclerosisAmyotrophic lateral sclerosisneurodegenerative disease10029317

NL-OMON49747Biogen1

进行中（未招募）

1 期

ong-Term Evaluation of BIIB067Amyotrophic Lateral Sclerosis (ALS)MedDRA version: 20.0Level: PTClassification code 10077024Term: Familial amyotrophic lateral sclerosisSystem Organ Class: 10010331 - Congenital, familial and genetic disordersMedDRA version: 21.1Level: PTClassification code 10002026Term: Amyotrophic lateral sclerosisSystem Organ Class: 10029205 - Nervous system disorders

EUCTR2016-003225-41-BEBiogen Idec Research Limited183

进行中（未招募）

1 期

EUCTR2016-003225-41-DEBiogen Idec Research Limited183

进行中（未招募）

1 期

EUCTR2016-003225-41-ESBiogen Idec Research Limited183